Steroid showdown: oral vs. injected for rare eye disease
NCT ID NCT07405489
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 30 people with Vogt-Koyanagi-Harada (VKH) disease, a rare autoimmune condition that causes eye inflammation and can lead to vision loss. Researchers compared two initial treatments: oral prednisolone (steroid pills) and steroid injections near the eye. They checked how well each controlled inflammation at 3 months and tracked vision changes and side effects over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oral prednisolone and posterior sub-Tenon triamcinolone acetonide (steroid injections near the eye)
- What this could lead to
- If one approach works better, it could point toward a safer, more effective first treatment for VKH eye inflammation, potentially reducing the need for systemic steroids.
- What could go wrong
- This is a small, retrospective study with only 30 participants, so results may not apply to everyone. It compares two existing treatments, not a new breakthrough, and cannot prove which is definitively better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study included treatment-naïve adult patients with acute ocular VKH disease who received either oral prednisolone or posterior sub-Tenon triamcinolone acetonide as initial therapy. All patients had bilateral disease; both eyes received the same treatment.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years Diagnosis of definite or probable acute ocular Vogt-Koyanagi-Harada (VKH) disease Active intraocular inflammation (choroiditis, serous retinal detachment, or panuveitis) No prior treatment for the current VKH episode Minimum follow-up of 6 months with complete medical records, including BCVA and OCT data Exclusion Criteria: * Prior systemic or periocular corticosteroid therapy for VKH Use of immunosuppressive or biologic agents at presentation Pre-existing glaucoma, ocular hypertension, or advanced cataract Retinal diseases affecting visual outcomes (e.g., diabetic retinopathy, age-related macular degeneration) Incomplete medical records or missing OCT/BCVA data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VKH syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Benha University
Banhā, Benha, 13111, Egypt